Corcept Therapeutics Inc [CORT] stock is trading at $76.22, up 1.87%. An important factor to consider is whether the stock is rising or falling in short-term value. The CORT shares have gain 7.98% over the last week, with a monthly amount glided 21.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on November 06, 2023, when Truist upgraded its rating to a Buy and also boosted its price target to $38 from $29. Previously, SVB Securities started tracking the stock with Market Perform rating on April 11, 2023, and set its price target to $25. On April 04, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $27 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $22 on February 15, 2023. Truist downgraded its rating to a Hold but $30 remained the price target by the analyst firm on August 01, 2022. Jefferies upgraded its rating to Buy for this stock on July 27, 2022, and upped its price target to $35.
Corcept Therapeutics Inc [CORT] stock has fluctuated between $27.30 and $117.33 over the past year. Currently, Wall Street analysts expect the stock to reach $140 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $76.22 at the most recent close of the market. An investor can expect a potential return of 83.68% based on the average CORT price forecast.
Analyzing the CORT fundamentals
Corcept Therapeutics Inc [NASDAQ:CORT] reported sales of 685.45M for the trailing twelve months, which represents a growth of 7.09%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.16%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.19%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.2 and Total Capital is 0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Corcept Therapeutics Inc’s Current Ratio is 3.07. On the other hand, the Quick Ratio is 2.96, and the Cash Ratio is 0.63. Considering the valuation of this stock, the price to sales ratio is 11.79, the price to book ratio is 11.82 and price to earnings (TTM) ratio is 66.16.
Transactions by insiders
Recent insider trading involved Guyer William, Chief Development Officer, that happened on May 16 ’25 when 32262.0 shares were sold. Director, MAHONEY DAVID L completed a deal on May 16 ’25 to sell 27352.0 shares. Meanwhile, Officer Robb Gary Charles bought 2279.0 shares on May 20 ’25.
